Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Mortality (calculated instead of overall survival) · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in mortality (instead of overall survival) compared with chemotherapy only (moderate certainty).
1 finding from 1 review
Quality of life · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality, relapse and progresses (instead of disease‐ or relapse‐free survival) · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in mortality, relapse and progresses (instead of disease‐ or… compared with chemotherapy only (moderate certainty).
1 finding from 1 review
On‐study mortality · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in on‐study mortality compared with chemotherapy only (moderate certainty).
1 finding from 1 review
Severe adverse effects (grade 3+): Infection · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in infection grade III/IV compared with chemotherapy only (moderate certainty).
1 finding from 1 review
Grade 3 to 4 diarrhoea · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
It is very uncertain whether ATRA in addition to chemotherapy changes diarrhoea grade III/IV compared with chemotherapy only (very low certainty).
1 finding from 1 review
Toxicity: grade 3 or 4 nausea ± vomiting · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
It is very uncertain whether ATRA in addition to chemotherapy changes nausea/vomiting grade III/IV compared with chemotherapy only (very low certainty).
1 finding from 1 review
Cardiac toxicity grade III/IV · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
It is very uncertain whether ATRA in addition to chemotherapy changes cardiac toxicity grade III/IV compared with chemotherapy only (very low certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
1 finding from 1 review
Progression‐free survival · people with metastatic CRC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response · people with metastatic CRC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse effects · people with metastatic CRC
Chemotherapy probably leads to higher severe adverse effects compared with best supportive care (moderate certainty).
1 finding from 1 review
Overall survival (OS) · recurrent platinum‐resistant EOC
Chemotherapy with TKI showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · recurrent platinum‐resistant EOC
Chemotherapy with TKI may leads to lower progression‐free survival (PFS) compared with chemotherapy alone (low certainty).
1 finding from 1 review
QoL · recurrent platinum‐resistant EOC
Chemotherapy with TKI showed no clear difference in quality of life (QoL) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
Chemotherapy with TKI may leads to higher any adverse events (grade ≥3) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Hypertension (grade ≥ 2)Â · recurrent platinum‐resistant EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bowel fistula / perforation (grade ≥ 3) · recurrent platinum‐resistant EOC
It is very uncertain whether chemotherapy with TKI changes bowel fistula / perforation (grade ≥ 3) compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus lower‐dose radiation showed no clear difference in secondary malignant neoplasms compared with same chemotherapy plus higher‐dose radiation (low certainty).
1 finding from 1 review